CO6341487A2 - Marcadores séricos que predicen la respuesta clínica a los anticuerpos anti tnf (alfa) en pacientes con espondilitis anquilosante - Google Patents
Marcadores séricos que predicen la respuesta clínica a los anticuerpos anti tnf (alfa) en pacientes con espondilitis anquilosanteInfo
- Publication number
- CO6341487A2 CO6341487A2 CO11081269A CO11081269A CO6341487A2 CO 6341487 A2 CO6341487 A2 CO 6341487A2 CO 11081269 A CO11081269 A CO 11081269A CO 11081269 A CO11081269 A CO 11081269A CO 6341487 A2 CO6341487 A2 CO 6341487A2
- Authority
- CO
- Colombia
- Prior art keywords
- markers
- patients
- therapy
- anquilosing
- preach
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención proporciona herramientas para el manejo de pacientes diagnosticados con espondilitis anquilosante antes de iniciar a terapia con un agente anti-TNF alfa. Las herramientas son marcadores y algoritmos específicos para predecir la respuesta a la terapia en base a puntos finales clínicos estándar primarios y secundarios con el uso de concentraciones de marcadores séricos. En una modalidad la concentración inicial de leptina u osteocalcina se usa para predecir a respuesta en la semana 14 después de iniciar la terapia. En otra modalidad después de 4 semanas de terapia se usa el cambio en un biomarcador proteico sérico, tal como el componente 3 del complemento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14142108P | 2008-12-30 | 2008-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6341487A2 true CO6341487A2 (es) | 2011-11-21 |
Family
ID=42310120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11081269A CO6341487A2 (es) | 2008-12-30 | 2011-06-29 | Marcadores séricos que predicen la respuesta clínica a los anticuerpos anti tnf (alfa) en pacientes con espondilitis anquilosante |
Country Status (12)
Country | Link |
---|---|
US (1) | US20110251099A1 (es) |
EP (1) | EP2384367A4 (es) |
JP (2) | JP5684724B2 (es) |
KR (1) | KR20110110247A (es) |
CN (1) | CN102272326B (es) |
AU (1) | AU2009333489A1 (es) |
BR (1) | BRPI0923806A2 (es) |
CA (1) | CA2750155A1 (es) |
CO (1) | CO6341487A2 (es) |
IL (1) | IL213245A (es) |
MX (1) | MX2011007030A (es) |
WO (1) | WO2010077722A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528160B2 (en) | 2008-11-07 | 2016-12-27 | Adaptive Biotechnolgies Corp. | Rare clonotypes and uses thereof |
US9506119B2 (en) | 2008-11-07 | 2016-11-29 | Adaptive Biotechnologies Corp. | Method of sequence determination using sequence tags |
US8748103B2 (en) | 2008-11-07 | 2014-06-10 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
US9365901B2 (en) | 2008-11-07 | 2016-06-14 | Adaptive Biotechnologies Corp. | Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia |
US8628927B2 (en) | 2008-11-07 | 2014-01-14 | Sequenta, Inc. | Monitoring health and disease status using clonotype profiles |
SG195652A1 (en) | 2008-11-07 | 2013-12-30 | Sequenta Inc | Methods of monitoring conditions by sequence analysis |
HUE029424T2 (en) | 2009-01-15 | 2017-02-28 | Adaptive Biotechnologies Corp | Adaptive immunity profiling and a method for producing monoclonal antibodies |
JP2012531202A (ja) | 2009-06-25 | 2012-12-10 | フレッド ハチンソン キャンサー リサーチ センター | 適応免疫を測定する方法 |
WO2011047358A1 (en) | 2009-10-15 | 2011-04-21 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
ES2564290T3 (es) | 2010-11-02 | 2016-03-21 | Kypha, Inc. | Inmunoensayo de flujo lateral para la activación de complemento y métodos de uso para evaluación del sitio de atención de trastornos asociados a complemento |
EP3384939A1 (en) | 2011-03-11 | 2018-10-10 | Vib Vzw | Molecules and methods for inhibition and detection of proteins |
US10385475B2 (en) | 2011-09-12 | 2019-08-20 | Adaptive Biotechnologies Corp. | Random array sequencing of low-complexity libraries |
EP2768982A4 (en) | 2011-10-21 | 2015-06-03 | Adaptive Biotechnologies Corp | QUANTIFICATION OF ADAPTIVE IMMUNOCELL GENOMES IN A COMPLEX MIX OF CELLS |
EP2773773B1 (en) * | 2011-11-04 | 2017-01-11 | Adaptive Biotechnologies Corporation | T-cell receptor clonotypes shared among ankylosing spondylitis patients |
EP2788509B1 (en) | 2011-12-09 | 2018-07-11 | Adaptive Biotechnologies Corporation | Diagnosis of lymphoid malignancies and minimal residual disease detection |
US9499865B2 (en) | 2011-12-13 | 2016-11-22 | Adaptive Biotechnologies Corp. | Detection and measurement of tissue-infiltrating lymphocytes |
EP2823060B1 (en) | 2012-03-05 | 2018-02-14 | Adaptive Biotechnologies Corporation | Determining paired immune receptor chains from frequency matched subunits |
US9275334B2 (en) * | 2012-04-06 | 2016-03-01 | Applied Materials, Inc. | Increasing signal to noise ratio for creation of generalized and robust prediction models |
DK2831276T3 (da) | 2012-05-08 | 2016-08-01 | Adaptive Biotechnologies Corp | Sammensætninger og fremgangsmåde til at måle og kalibrere amplifikations-bias i multipleks-PCR-reaktioner |
ES2749118T3 (es) | 2012-10-01 | 2020-03-19 | Adaptive Biotechnologies Corp | Evaluación de la inmunocompetencia por la diversidad de los receptores de inmunidad adaptativa y caracterización de la clonalidad |
WO2015160439A2 (en) | 2014-04-17 | 2015-10-22 | Adaptive Biotechnologies Corporation | Quantification of adaptive immune cell genomes in a complex mixture of cells |
US9708657B2 (en) | 2013-07-01 | 2017-07-18 | Adaptive Biotechnologies Corp. | Method for generating clonotype profiles using sequence tags |
JP6512828B2 (ja) | 2014-01-07 | 2019-05-15 | 三星電子株式会社Samsung Electronics Co.,Ltd. | c−Met阻害剤の効能予測または効能検証のためのバイオマーカー |
EP2899543A1 (en) * | 2014-01-28 | 2015-07-29 | Predemtec GmbH | Biomarker and methods for early diagnosis of Alzheimer's disease |
WO2015134787A2 (en) | 2014-03-05 | 2015-09-11 | Adaptive Biotechnologies Corporation | Methods using randomer-containing synthetic molecules |
US10066265B2 (en) | 2014-04-01 | 2018-09-04 | Adaptive Biotechnologies Corp. | Determining antigen-specific t-cells |
CA2943821A1 (en) | 2014-04-02 | 2015-10-08 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring juvenile idiopathic arthritis activity |
CA2950771A1 (en) * | 2014-06-10 | 2015-12-17 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring axial spondyloarthritis disease activity |
CN105372431A (zh) * | 2014-08-15 | 2016-03-02 | 同济大学附属上海市肺科医院 | 一组结节病血清特异性标志蛋白及其检测试剂盒 |
CA2966201A1 (en) | 2014-10-29 | 2016-05-06 | Adaptive Biotechnologies Corp. | Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples |
US10246701B2 (en) | 2014-11-14 | 2019-04-02 | Adaptive Biotechnologies Corp. | Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture |
US11066705B2 (en) | 2014-11-25 | 2021-07-20 | Adaptive Biotechnologies Corporation | Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing |
AU2016222788B2 (en) | 2015-02-24 | 2022-03-31 | Adaptive Biotechnologies Corp. | Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing |
AU2016242967B2 (en) | 2015-04-01 | 2021-07-01 | Adaptive Biotechnologies Corp. | Method of identifying human compatible T cell receptors specific for an antigenic target |
CA3207751A1 (en) | 2015-09-29 | 2017-04-06 | Laboratory Corporation Of America Holdings | Biomarkers and methods for assessing psoriatic arthritis disease activity |
WO2017058999A2 (en) | 2015-09-29 | 2017-04-06 | Crescendo Bioscience | Biomarkers and methods for assessing response to inflammatory disease therapy withdrawal |
EP3150716A1 (en) | 2015-09-29 | 2017-04-05 | Institut Pasteur | Immunological signatures and parameters predicting therapeutic responses to anti-tnf therapy |
US10018637B2 (en) | 2015-10-06 | 2018-07-10 | Celgene International Ii Sarl | Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast |
EP3359967B1 (en) * | 2015-10-06 | 2021-08-18 | Amgen (Europe) GmbH | Methods for treating inflammatory and other diseases and the use of biomarkers as predictors of clinical sensitivity to treatment with apremilast |
GB2547406A (en) * | 2015-11-20 | 2017-08-23 | Folkersen Lasse | Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response |
US11694802B2 (en) * | 2016-01-22 | 2023-07-04 | Otraces Inc. | Systems and methods for improving diseases diagnosis |
US10428325B1 (en) | 2016-09-21 | 2019-10-01 | Adaptive Biotechnologies Corporation | Identification of antigen-specific B cell receptors |
WO2018147915A1 (en) | 2017-02-07 | 2018-08-16 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
US20180299445A1 (en) * | 2017-04-03 | 2018-10-18 | Biodetego Llc | Biomarkers and methods of using same |
US11254980B1 (en) | 2017-11-29 | 2022-02-22 | Adaptive Biotechnologies Corporation | Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements |
JP6954568B2 (ja) * | 2020-03-31 | 2021-10-27 | クラシエホールディングス株式会社 | 健康管理支援システム、健康管理支援方法、及びプログラム |
CA3205027A1 (en) * | 2020-12-17 | 2022-06-23 | Janssen Biotech, Inc. | Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0746107B2 (ja) * | 1987-04-27 | 1995-05-17 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 検定法 |
US6451983B2 (en) | 1989-08-07 | 2002-09-17 | Peptech Limited | Tumor necrosis factor antibodies |
US5959087A (en) | 1989-08-07 | 1999-09-28 | Peptide Technology, Ltd. | Tumour necrosis factor binding ligands |
WO1991003553A1 (en) | 1989-09-05 | 1991-03-21 | Immunex Corporation | TUMOR NECROSIS FACTOR-α AND -β RECEPTORS |
US5656272A (en) | 1991-03-18 | 1997-08-12 | New York University Medical Center | Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies |
US5637469A (en) | 1992-05-01 | 1997-06-10 | Trustees Of The University Of Pennsylvania | Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems |
AU670125B2 (en) | 1992-09-15 | 1996-07-04 | Immunex Corporation | Method of treating tnf-dependent inflammation using tumor necrosis factor antagonists |
US5972703A (en) * | 1994-08-12 | 1999-10-26 | The Regents Of The University Of Michigan | Bone precursor cells: compositions and methods |
US5571410A (en) | 1994-10-19 | 1996-11-05 | Hewlett Packard Company | Fully integrated miniaturized planar liquid sample handling and analysis device |
CA2213854C (en) | 1995-03-10 | 2010-08-10 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
US6207369B1 (en) | 1995-03-10 | 2001-03-27 | Meso Scale Technologies, Llc | Multi-array, multi-specific electrochemiluminescence testing |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
HU230048B1 (hu) | 1996-02-09 | 2015-06-29 | Abbvie Biotechnology Ltd | Humán TNFalfa-kötő antitestek alkalmazása |
US5942443A (en) | 1996-06-28 | 1999-08-24 | Caliper Technologies Corporation | High throughput screening assay systems in microscale fluidic devices |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
US6537749B2 (en) | 1998-04-03 | 2003-03-25 | Phylos, Inc. | Addressable protein arrays |
US6576478B1 (en) | 1998-07-14 | 2003-06-10 | Zyomyx, Inc. | Microdevices for high-throughput screening of biomolecules |
US6406921B1 (en) | 1998-07-14 | 2002-06-18 | Zyomyx, Incorporated | Protein arrays for high-throughput screening |
WO2000056934A1 (en) | 1999-03-24 | 2000-09-28 | Packard Bioscience Company | Continuous porous matrix arrays |
WO2001031579A2 (en) | 1999-10-27 | 2001-05-03 | Barnhill Technologies, Llc | Methods and devices for identifying patterns in biological patterns |
US20070172449A1 (en) * | 2000-03-02 | 2007-07-26 | Xencor, Inc. | TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS |
AU2001280581A1 (en) | 2000-07-18 | 2002-01-30 | Correlogic Systems, Inc. | A process for discriminating between biological states based on hidden patterns from biological data |
UA81743C2 (uk) | 2000-08-07 | 2008-02-11 | Центокор, Инк. | МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ |
WO2002042733A2 (en) | 2000-11-16 | 2002-05-30 | Ciphergen Biosystems, Inc. | Method for analyzing mass spectra |
WO2004074511A1 (en) * | 2003-02-21 | 2004-09-02 | Garvan Institute Of Medical Research | Diagnosis and treatment of baff-mediated autoimmune diseases and cancer |
CA2537818A1 (en) * | 2003-09-15 | 2005-03-31 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases |
US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
US20060286571A1 (en) * | 2005-04-28 | 2006-12-21 | Prometheus Laboratories, Inc. | Methods of predicting methotrexate efficacy and toxicity |
EP2312315A1 (en) * | 2005-05-18 | 2011-04-20 | Novartis AG | Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component |
RU2438704C2 (ru) | 2005-11-01 | 2012-01-10 | Эбботт Байотекнолоджи Лтд. | Способы и композиции для диагностики анкилозирующих спондилитов с использованием биомаркеров |
KR20080094803A (ko) * | 2006-01-27 | 2008-10-24 | 트리패스 이미징, 인코포레이티드 | 난소암의 발병 가능성이 높은 환자를 확인하는 방법 및 그의 조성물 |
JP5237366B2 (ja) * | 2007-06-20 | 2013-07-17 | メルク・シャープ・アンド・ドーム・コーポレーション | 炎症性関節疾患に対する抗il−17a治療のための関節破壊のバイオマーカー |
-
2009
- 2009-12-09 AU AU2009333489A patent/AU2009333489A1/en not_active Abandoned
- 2009-12-09 JP JP2011544452A patent/JP5684724B2/ja active Active
- 2009-12-09 EP EP09836754.3A patent/EP2384367A4/en not_active Withdrawn
- 2009-12-09 BR BRPI0923806-9A patent/BRPI0923806A2/pt not_active IP Right Cessation
- 2009-12-09 CA CA2750155A patent/CA2750155A1/en not_active Abandoned
- 2009-12-09 MX MX2011007030A patent/MX2011007030A/es not_active Application Discontinuation
- 2009-12-09 US US13/140,441 patent/US20110251099A1/en not_active Abandoned
- 2009-12-09 CN CN200980153744.4A patent/CN102272326B/zh not_active Expired - Fee Related
- 2009-12-09 KR KR1020117017606A patent/KR20110110247A/ko not_active Application Discontinuation
- 2009-12-09 WO PCT/US2009/067282 patent/WO2010077722A1/en active Application Filing
-
2011
- 2011-05-31 IL IL213245A patent/IL213245A/en not_active IP Right Cessation
- 2011-06-29 CO CO11081269A patent/CO6341487A2/es not_active Application Discontinuation
-
2014
- 2014-06-05 JP JP2014116798A patent/JP2014197013A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL213245A (en) | 2014-09-30 |
JP2014197013A (ja) | 2014-10-16 |
BRPI0923806A2 (pt) | 2015-07-14 |
KR20110110247A (ko) | 2011-10-06 |
WO2010077722A1 (en) | 2010-07-08 |
IL213245A0 (en) | 2011-07-31 |
JP5684724B2 (ja) | 2015-03-18 |
JP2012514208A (ja) | 2012-06-21 |
CA2750155A1 (en) | 2010-07-08 |
EP2384367A4 (en) | 2013-07-10 |
EP2384367A1 (en) | 2011-11-09 |
CN102272326B (zh) | 2014-11-12 |
AU2009333489A1 (en) | 2010-07-08 |
CN102272326A (zh) | 2011-12-07 |
US20110251099A1 (en) | 2011-10-13 |
MX2011007030A (es) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6341487A2 (es) | Marcadores séricos que predicen la respuesta clínica a los anticuerpos anti tnf (alfa) en pacientes con espondilitis anquilosante | |
AR122765A2 (es) | Selección de sitios de muestreo para tratamientos agrícolas | |
CY1119262T1 (el) | Αναλυτικες μεθοδοι και συστοιχιες για χρηση στην ταυτοποιηση παραγοντων που επαγουν ευαισθητοποιηση στο ανθρωπινο δερμα | |
BR112014018331A8 (pt) | Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação | |
EA200971131A1 (ru) | Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам | |
GT201500249A (es) | Terapia de combinación | |
ECSP088618A (es) | Composiciones y métodos de uso para anticuerpos de dickkopf-1 y/o -4 | |
CO6440590A2 (es) | Plataforma de desarrollo de administración de terapia | |
CY1121607T1 (el) | Θεραπεια των αρνητικων συμπτωματων της σχιζοφρενιας με το (r)-7-χλωρο-ν-(κινουκλιδιν-3-υλ) βενζο[β]θειοφενο-2-καρβοξαμιδιο και φαρμακευτικα αποδεκτα αλατα αυτου | |
PE20130983A1 (es) | Metodo para evaluar el riesgo de nacimientos multiples en tratamientos de infertilidad | |
BR112014018970A8 (pt) | Dispositivos de coleta de amostra com agentes de estabilização sanguínea | |
AR051925A1 (es) | Anticuerpos anti-ox4ol | |
ES2494915T3 (es) | P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico | |
AR057323A1 (es) | Metodo para la prediccion de la respuesta a un tratamiento | |
CL2016000042A1 (es) | Uso de una combinación de un inhibidor de mek y un inhibidor de erk para el tratamiento de enfermedades hiperproliferativas. | |
PE20191359A1 (es) | Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5 | |
AR054357A1 (es) | Metodo para evaluar la efectividad de un regimen de tratamiento | |
BR112017005801A2 (pt) | anticorpo capaz de neutralizar a substância tendo atividade alternativa para função de fator de coagulação viii (fviii) | |
ECSP22094536A (es) | Anticuerpos contra el sars-cov-2 y métodos de selección y uso de los mismos | |
CY1111609T1 (el) | Αγωγη υποκειμενων με χρονια νεφρικη νοσο (ckd) με τη χρηση ενωσεων λανθανιου | |
AR061100A1 (es) | Metodos y composiciones para el tratamiento de enfermedades o condiciones asociadas con aumento de niveles de proteina c reactiva, interleuquina - 6 o interferon gamma | |
BRPI0808599A2 (pt) | "ácido nucléico, vacina, composição farmacêutica, uso de um ácido nucléico e método para estimular uma imunoresposta versus um epítopo das células t" | |
AR090738A1 (es) | Metodos para el tratamiento de espondilitis anquilosante usando antagonistas de il-17 | |
BR112017017878A2 (pt) | método, suporte e kit de coleta de ácido(s) nucleico(s) | |
CY1119912T1 (el) | Αντιγονα και συνδυασμοι αντιγονων pseudomonas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |